Hiprex is a urinary antiseptic, not an antibiotic. Its active ingredient, methenamine hippurate, works by generating formaldehyde in acidic urine rather than by targeting bacteria through the selective biochemical pathways that define antibiotics. This distinction matters more than it might seem at first glance, because the difference in mechanism shapes everything from resistance risk to who the drug works best for and how you need to take it.
What the Distinction Actually Means
Antibiotics are designed to interfere with specific biological processes inside bacteria. Some block cell-wall construction, others jam the machinery that copies DNA or builds proteins. Because each antibiotic targets a particular structure or enzyme, bacteria can evolve workarounds: a single mutation or a borrowed gene can neutralize the drug. That is the engine behind antibiotic resistance.
Methenamine hippurate sidesteps that entire dynamic. Once it reaches the bladder, it breaks down into two components: formaldehyde and hippuric acid. Formaldehyde is a blunt chemical weapon. Rather than picking one bacterial lock, it damages proteins and nucleic acids broadly, killing or inhibiting virtually any microorganism it contacts at sufficient concentration.1Pharmaceutical and Biomedical Research. The Forgotten Role of Methenamine to Prevent Recurrent Urinary Tract Infection: Urgency for Reuse 100 Years After Discovery The hippuric acid portion serves a supporting role by helping keep urine acidic, which is the chemical environment formaldehyde needs to form in the first place.2BMJ Open. Methenamine hippurate to prevent recurrent urinary tract infections in older women: protocol for a randomised, placebo-controlled trial (ImpresU)
This is why methenamine is classified as a urinary antiseptic. Antiseptics destroy or inhibit microorganisms through nonspecific chemical action rather than by exploiting a specific biological vulnerability. Bleach is an antiseptic. So is rubbing alcohol. Formaldehyde belongs to the same family of broad-acting antimicrobial chemicals. The difference is that Hiprex delivers its antiseptic payload in a targeted location: the urinary tract, specifically wherever urine is acidic enough to trigger the chemical reaction.
Why This Matters for Antibiotic Resistance
The practical payoff of the antiseptic classification is resistance, or rather the lack of it. Because formaldehyde attacks bacteria indiscriminately rather than through a single pathway, bacteria have an extremely difficult time developing resistance to it. There is no single gene to mutate, no single pump to upregulate. At adequate concentrations in acidic urine, formaldehyde overwhelms bacterial defenses.3Pharmaceutical and Biomedical Research. The Forgotten Role of Methenamine to Prevent Recurrent Urinary Tract Infection: Urgency for Reuse 100 Years After Discovery Methenamine has been in clinical use for well over a century, and meaningful resistance has still not been documented.
The ALTAR trial, one of the largest head-to-head comparisons of methenamine hippurate against daily antibiotic prophylaxis, provided concrete data on this point. During treatment, about 72% of women taking daily antibiotics showed antibiotic-resistant E. coli on perineal swabs, compared with 56% in the methenamine group.4NIHR Journals Library. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT That gap is significant for anyone dealing with recurrent infections: every course of prophylactic antibiotics nudges the bacteria living in and around the urinary tract toward resistance, making future infections harder to treat. Methenamine does this to a lesser degree.
One curious wrinkle from the same trial: after treatment stopped, the methenamine group actually showed slightly higher rates of multidrug-resistant E. coli than the antibiotic group, though the difference did not reach statistical significance. Researchers are still sorting out why, but it is a reminder that the resistance picture is not perfectly one-sided even with a non-antibiotic agent.
How Well Does It Actually Work
The evidence is encouraging, though the honest answer is that methenamine hippurate is not quite as potent as daily low-dose antibiotics at preventing recurrent urinary tract infections. In the ALTAR trial, women taking methenamine hippurate experienced roughly 1.4 symptomatic UTI episodes per person-year, compared with about 0.9 episodes per person-year in the antibiotic group. That half-episode difference fell within the trial’s pre-specified non-inferiority margin, meaning the researchers concluded methenamine was “not meaningfully worse” by their definition.5PubMed. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT
Whether that margin feels acceptable depends on your situation. If you are getting five or six UTIs a year and the choice is between daily antibiotics with creeping resistance or methenamine with perhaps one more breakthrough infection annually, many people and their doctors reasonably choose methenamine. A broader review of the available studies in older adults reached a similar conclusion: across the trials examined, methenamine consistently reduced the incidence of UTIs or bacteriuria compared with placebo or no treatment.6PubMed Central. Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence
It is worth emphasizing that methenamine hippurate is a preventive tool, not a treatment for an active infection. When you already have a UTI with symptoms, you need an antibiotic to clear the bacteria. Hiprex is designed to keep the bladder hostile to bacteria between infections, reducing how often the next one shows up.
The pH Problem
The effectiveness of methenamine hippurate depends entirely on urine pH. Formaldehyde only forms in meaningful amounts when urine is acidic, generally below a pH of about 5.5 to 6.0. If your urine is consistently neutral or alkaline, the drug sits in the bladder without converting into its active form, and you get little to no benefit.
This is why some clinicians recommend acidifying agents alongside methenamine. Vitamin C (ascorbic acid) is the most commonly suggested one, on the logic that extra acid in the diet should lower urine pH. The actual evidence for this is surprisingly weak. A study of elderly catheterized patients found that increasing doses of ascorbic acid did not reliably acidify urine and may have even raised pH in some cases.7PubMed. Appraisal of ascorbic acid for acidifying the urine of methenamine-treated geriatric patients The body tightly regulates acid-base balance, and the kidneys are quite good at buffering out extra acid before it reaches the bladder.
Diet can influence urine pH to some extent. High-protein diets tend to produce more acidic urine. Vegetarian and high-fruit diets often produce more alkaline urine. But the effect is modest and inconsistent. If your doctor prescribes Hiprex, checking your urine pH with inexpensive test strips at home can tell you whether conditions in your bladder are actually right for the drug to work. This is an underused step that can explain why some people get great results and others feel like the drug does nothing.
Which Bacteria It Covers
Because formaldehyde kills indiscriminately, methenamine hippurate has a remarkably broad spectrum of activity when it works. In laboratory testing, urine collected from people who had taken methenamine hippurate inhibited the growth of E. coli, Pseudomonas, Proteus, and Enterobacter, which covers most of the common urinary pathogens.8Investigative Urology. Antibacterial correlates of urine drug levels of hexamethylenetetramine and formaldehyde That breadth is unusual for a single drug and is a direct consequence of how nonspecific the killing mechanism is.
There is one important exception. Bacteria that split urea, particularly certain Proteus species, raise urine pH as a byproduct of their metabolism. In other words, the very act of these bacteria colonizing the bladder can push the environment away from the acidic conditions methenamine needs. This creates a frustrating paradox: the drug’s chemical activation is undermined by the pathogen it is supposed to fight. In practice, urea-splitting infections are a minority of UTIs, but they are more common in people with structural urinary abnormalities or long-term catheters.
Spinal Cord Injury and Catheterized Patients
People with neurogenic bladders from spinal cord injuries represent one of the more studied special populations for methenamine. The results are genuinely mixed. One study of 56 patients using intermittent catheterization found that those receiving methenamine had positive urine cultures only about 23% of the time, compared with roughly 58% in the untreated control group.9PubMed. Decreased incidence of urinary tract infections in patients with spinal cord injury: effect of methenamine That looks compelling.
But a larger randomized trial, the SINBA study, found no significant benefit. Patients given methenamine hippurate did not stay UTI-free longer than those on placebo.10Spinal Cord. Spinal-injured neuropathic bladder antisepsis (SINBA) trial The likely explanation circles back to the pH problem. Catheterized patients often have alkaline urine, partly because of bacterial colonization and partly because of reduced bladder emptying. If the urine never becomes acidic enough, the drug never activates. The earlier positive study may have included patients whose urine happened to be more acidic, or it may reflect the inherent variability in small trials.
For people in this situation, methenamine is not automatically useless, but it requires more attention to urine pH monitoring and may need to be paired with dietary or medication strategies to keep the urine acidic. A blanket prescription without checking pH is unlikely to help.
Side Effects and Safety
One of the genuine selling points of methenamine hippurate is how well tolerated it tends to be. A systematic review of recent evidence found that adverse effects were similar to those seen with comparator treatments and were generally mild: nausea, abdominal pain, and headache were the most commonly reported.11PubMed. Use of Methenamine for Urinary Tract Infection Prophylaxis: Systematic Review of Recent Evidence Compared with daily antibiotics, which can cause yeast infections, diarrhea, and the gradual erosion of your gut microbiome, that profile looks favorable.
There are a few cautions. Methenamine should not be used in people with severe kidney impairment, because formaldehyde can accumulate. It should also be avoided in people with severe liver disease or dehydration, which can alter how the drug is processed. Long-term use at very high doses has been linked to bladder irritation in rare cases, presumably because formaldehyde is not gentle on any tissue it contacts in high concentrations. At the standard dose of one gram twice daily, this is uncommon.
Pregnant women are generally advised to avoid methenamine, not because of strong evidence of harm but because formaldehyde crosses the placenta and no one has run the kind of safety trials that would be needed to clear it for use in pregnancy. Sulfonamide antibiotics should not be combined with methenamine, because the interaction can produce insoluble crystals in the urine.
A Drug Older Than Antibiotics Themselves
Methenamine was first synthesized in 1859 and introduced into medical practice in 1894, making it one of the oldest antimicrobial agents still in clinical use. It predates penicillin by several decades.12PubMed Central. An oldie but a goodie: Methenamine as a nonantibiotic solution to the prevention of recurrent urinary tract infections For most of the twentieth century it was a workhorse for UTI prevention, but it fell out of favor as antibiotics became cheap, effective, and widely prescribed. Why bother with a finicky antiseptic that needs acidic urine when you could hand someone trimethoprim and be done with it?
The resurgence of interest in methenamine tracks directly with the antimicrobial resistance crisis. As the go-to prophylactic antibiotics become less reliable and public health agencies urge clinicians to reduce unnecessary antibiotic prescribing, a century-old drug that does not contribute to resistance suddenly looks appealing again. Prescription data from Norway, where methenamine hippurate has remained more commonly used than in many other countries, shows increasing use over recent years, particularly in older populations.13Dove Medical Press. Use of Methenamine Hippurate in an Ageing Population: National Prescription Trends from Norway (2004–2020)
Hiprex Versus Mandelate Versus Other Formulations
Hiprex is a brand name for methenamine hippurate. You may also encounter methenamine mandelate, sold under other brand names. Both contain the same active core molecule, methenamine, but they differ in the acid they are paired with. Hippurate is paired with hippuric acid; mandelate is paired with mandelic acid. Both acids serve the same purpose: helping keep urine acidic so that formaldehyde can form.
In practice, the two formulations are used interchangeably for UTI prevention. Methenamine hippurate is more commonly prescribed in many countries and has more recent trial data behind it, including the ALTAR trial. Methenamine mandelate has older evidence supporting it and is still available in some markets. There is no strong evidence that one is meaningfully superior to the other, though hippurate tends to be the default in current clinical guidelines simply because the recent trials used it.
Generic methenamine hippurate is widely available and generally inexpensive, which is another practical advantage over some antibiotic alternatives. The standard prophylactic dose is one gram taken twice daily, typically with food to reduce the mild gastrointestinal effects some people experience.
When Hiprex Is Not the Right Choice
Methenamine hippurate works best in a fairly specific scenario: someone with a history of recurrent uncomplicated UTIs who wants to reduce how often they happen without relying on daily antibiotics. It is a preventive measure, not a rescue drug. If you are in the middle of an active infection with fever, pain, and urgency, you need an antibiotic, not an antiseptic that takes hours to build up formaldehyde levels in the bladder.
It is also a poor fit for people with structural urinary abnormalities that prevent complete bladder emptying, unless pH is carefully monitored. Residual urine that sits in the bladder can become alkaline over time, deactivating the drug. Similarly, anyone taking medications or eating a diet that consistently alkalinizes urine, including heavy use of antacids or sodium bicarbonate, may find methenamine ineffective.
People with kidney stones, particularly struvite stones, should use methenamine cautiously. Struvite stones are associated with urea-splitting bacteria, and the pH dynamics in these patients often work against formaldehyde production. And as mentioned, anyone with significant renal impairment should avoid it entirely, because the kidneys need to be functional both to excrete the drug into the urine and to clear formaldehyde from the body.
For people who do fit the profile, though, methenamine hippurate occupies a genuinely useful niche. It is not as potent as daily antibiotics at preventing every breakthrough UTI, but it avoids the resistance trade-off, is well tolerated, and has been doing the same job for over a hundred years without losing its effectiveness. In a medical landscape increasingly worried about running out of working antibiotics, that kind of staying power is worth paying attention to.